- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Drug Safety alert: CDSCO flags 78 drug samples
Overview
In its latest drug safety alert, the apex drug regulatory body, Central Drug Standard Control Organisation (CDSCO) has flagged 78 medicine batches for failing to qualify for a random drug sample test for December– 2023.
These include Montelukast Sodium and Levocetirizine Dihydrochloride Tablets manufactured by Bonsai Pharma, Multi-Vitamin Tablets (VITAJACKS-S TABLETS) manufactured by Jackson Laboratories, Telmisartan and Amlodipine Tablets IP (Zensartan-AM Tablets) manufactured by Windlass Biotech Limited, Telmisartan Tablets IP 40 mg (Telmibeck-40 Tablets) manufactured by Biocore Pharmaceuticals, Pregabalin Capsules IP (Pragavir Capsules) manufactured by Mayoford Pharma.
For the full story, check out the link given below:
CDSCO Drug Alert: 78 Drug Samples Including Alkem's Pan 40 Flagged